WEBULL
News
MIST
1.700
-1.16%
-0.020
Milestone Pharmaceuticals appoints Sandoval as General Counsel, CCO
TipRanks · 4d ago
Milestone Pharmaceuticals Names David Sandoval General Counsel and Chief Compliance Officer
Reuters · 4d ago
MILESTONE PHARMACEUTICALS APPOINTS DAVID SANDOVAL AS GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER
Reuters · 4d ago
Press Release: Milestone Pharmaceuticals Appoints -2-
Dow Jones · 4d ago
Weekly Report: what happened at MIST last week (0202-0206)?
Weekly Report · 5d ago
Milestone Pharmaceuticals Grants 419,000 Stock Options to New Employees
Reuters · 02/03 13:03
MILESTONE PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 02/03 13:00
Weekly Report: what happened at MIST last week (0126-0130)?
Weekly Report · 02/02 09:13
Milestone Pharmaceuticals Chief Medical Officer David Bharucha Reports Disposal of Common Shares
Reuters · 01/28 23:30
Milestone Pharmaceuticals CEO Joseph Oliveto Reports Disposal of Common Shares
Reuters · 01/28 23:30
Milestone Pharmaceuticals Chief Commercial Officer Lorenz Muller Reports Disposal of Common Shares
Reuters · 01/28 23:30
Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
TipRanks · 01/26 14:51
Milestone Pharmaceuticals announces U.S. availability of cardamyst
TipRanks · 01/26 13:10
Milestone Pharmaceuticals Announces Availability Of Cardamyst (Etripamil) Nasal Spray, Its First Commercial Product, Through US Retail Pharmacies
Benzinga · 01/26 13:05
MILESTONE PHARMACEUTICALS INC - COPAYS FOR ELIGIBLE INSURED PATIENTS EXPECTED TO BE CAPPED AT $25
Reuters · 01/26 13:00
Weekly Report: what happened at MIST last week (0119-0123)?
Weekly Report · 01/26 09:13
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Barchart · 01/26 07:00
Weekly Report: what happened at MIST last week (0112-0116)?
Weekly Report · 01/19 09:14
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense
Seeking Alpha · 01/15 14:45
More
Webull provides a variety of real-time MIST stock news. You can receive the latest news about Milestone Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.